Aytu BioPharma, Inc. — Form 10-Q Summary
Period clarification: The filing covers the three months ended September 30, 2020, Aytu’s fiscal first quarter of 2021. This differs from the request metadata label “2020 Q1.”
Business context and reporting period
Aytu is a commercial-stage specialty pharmaceutical company with prescription and consumer health businesses. Its portfolio includes primary-care products, the pediatric portfolio acquired from Cerecor in November 2019, and consumer health products acquired through the Innovus merger completed in February 2020. The quarter’s comparison with September 2019 does not include those acquired businesses in the prior-year period.
Key financial results and liquidity
| Metric | Three months ended September 30, 2020 | Prior-year period |
|---|---|---|
| Revenue | $13.52 million | $1.44 million |
| Gross profit and margin | $9.70 million; approximately 71.8% | $1.06 million; approximately 73.9% |
| Operating loss | $3.56 million | $4.74 million |
| Net loss | $4.31 million; $0.04 per share | $4.93 million; $0.32 per share |
| Cash used in operating activities | $7.97 million | $2.99 million |
Revenue rose 839%, principally reflecting contributions from the pediatric portfolio ($2.72 million) and Innovus Consumer Health ($7.77 million). Primary care and devices revenue was $3.03 million. The filing reports no formal gross-margin discussion; margins above are calculated from reported revenue and cost of sales.
At September 30, 2020, cash and cash equivalents were $37.91 million and restricted cash was $0.25 million. Current assets were $65.45 million versus current liabilities of $21.51 million. Total assets were $141.27 million, total liabilities $50.21 million, and stockholders’ equity $91.06 million. The balance sheet reports $0.93 million of current debt; it also reports fixed-payment arrangements, contingent consideration, and CVR liabilities, which are additional obligations and should not be conflated with that debt line.
Cash, restricted cash, and cash equivalents fell by $10.17 million during the quarter. Investing activities used $0.02 million and financing activities used $2.18 million, including $1.63 million of offering-related costs. Operating cash use exceeded net loss, with working-capital changes among the principal factors.
Material changes versus the prior comparable period
- Revenue expansion largely reflects the two acquisitions, rather than solely organic growth. SG&A increased 123% to $11.49 million, and intangible amortization increased to $1.58 million, also largely due to the acquired businesses.
- Despite substantially higher revenue and operating expenses, operating loss narrowed by $1.18 million and net loss narrowed by $0.62 million.
- Operating cash use increased by about $4.99 million year over year. Management attributed the increase to acquisition integration, working-capital needs, and liability payments.
- Cash and cash equivalents declined from $48.08 million at June 30, 2020 to $37.91 million at September 30, 2020. No ATM shares were sold during the quarter; after quarter-end, the company reported approximately $3.1 million of gross proceeds from issuing approximately 3.0 million shares.
Outlook, commentary, risks, and unusual items
- Management expects revenue to increase over time and operating cash needs to decline, while also expecting modestly higher costs as it integrates the acquisitions and pursues sales growth. The filing provides no specific revenue, earnings, or cash-flow guidance.
- Management said cash on hand was sufficient for anticipated net cash outflows for the 12 months following filing and reported no substantial doubt about the company’s ability to continue as a going concern. It nevertheless cautioned that future financing may be needed and may not be available on favorable terms or at all.
- If capital is insufficient, management may reduce commercial programs, headcount, or R&D, narrow commercial plans, or renegotiate product rights; these actions could affect growth and potentially lead to impairment charges.
- Disclosed contractual commitments and contingencies totaled approximately $37.49 million, including pediatric fixed payments and product minimums, Innovus CVRs, inventory purchases, and potential product milestones. These amounts have differing terms and contingencies; they are not all necessarily currently payable.
- The company recognized a $343,000 gain on termination of an Innovus lease and a $112,000 loss on equipment sold in connection with lease terminations. It recorded a $100,000 inventory write-down.
- Aytu holds U.S. distribution rights to COVID-19 antibody tests and a license to Healight, an investigational device platform. Management described Healight as preclinical and planned further development and human studies; commercialization depends on clinical effectiveness and manufacturing feasibility.
- Legal matters included a proposed Presmar settlement subject to board approval, a Hikma supply settlement with purchase commitments, a Marin County advertising matter awaiting court approval of a stipulated judgment, and previously dismissed shareholder actions for which mootness-fee motions remained possible.
Important facts for investors to verify
- How much of revenue growth is sustainable and organic, and how acquired-business sales and profitability trend in subsequent filings.
- Whether operating cash use and working-capital requirements decline as management expects, and the company’s remaining cash runway.
- The timing, terms, and cash or dilution impact of fixed-payment, royalty, minimum-sales, milestone, and CVR obligations.
- The effect of the post-quarter ATM issuance and any further equity financing on share count and dilution; 125.84 million shares were outstanding at September 30, 2020.
- Progress, regulatory status, and development costs for COVID-19 testing and Healight, as well as the resolution and potential costs of disclosed legal matters.